A
Anton G. Henssen
Researcher at Charité
Publications - 85
Citations - 2049
Anton G. Henssen is an academic researcher from Charité. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 17, co-authored 58 publications receiving 1047 citations. Previous affiliations of Anton G. Henssen include University of Düsseldorf & Max Delbrück Center for Molecular Medicine.
Papers
More filters
Journal ArticleDOI
Mutational dynamics between primary and relapse neuroblastomas
Alexander Schramm,Johannes Köster,Johannes Köster,Yassen Assenov,Kristina Althoff,Martin Peifer,E Mahlow,Andrea Odersky,Daniela Beisser,Corinna Ernst,Anton G. Henssen,Anton G. Henssen,Anton G. Henssen,Harald Stephan,Christopher Schröder,Lukas C. Heukamp,Anne Engesser,Yvonne Kahlert,Jessica Theissen,Barbara Hero,Frederik Roels,Janine Altmüller,Peter Nürnberg,Kathy Astrahantseff,Christian Gloeckner,Katleen De Preter,Christoph Plass,Sangkyun Lee,Holger N. Lode,Kai Oliver Henrich,Moritz Gartlgruber,Frank Speleman,Peter Schmezer,Frank Westermann,Sven Rahmann,Sven Rahmann,Matthias Fischer,Angelika Eggert,Angelika Eggert,Johannes H. Schulte,Johannes H. Schulte,Johannes H. Schulte +41 more
TL;DR: The mutational burden significantly increased in relapsing tumors, accompanied by altered mutational signatures and reduced subclonal heterogeneity and global allele frequencies at relapse indicated clonal mutation selection during disease progression.
Journal ArticleDOI
Extrachromosomal DNA is associated with oncogene amplification and poor outcome across multiple cancers.
Hoon Kim,Nam-Phuong Nguyen,Kristen M. Turner,Sihan Wu,Amit D. Gujar,Jens Luebeck,Jihe Liu,Viraj Deshpande,Viraj Deshpande,Utkrisht Rajkumar,Sandeep Namburi,Samirkumar B. Amin,Eun Hee Yi,Francesca Menghi,Johannes H. Schulte,Anton G. Henssen,Anton G. Henssen,Howard Y. Chang,Howard Y. Chang,Christine R. Beck,Paul S. Mischel,Paul S. Mischel,Vineet Bafna,Roel G.W. Verhaak +23 more
TL;DR: It is demonstrated that ecDNA-based oncogene amplification is common in cancer, is different from chromosomal amplification and drives poor outcome for patients across many cancer types.
Journal ArticleDOI
Extrachromosomal circular DNA drives oncogenic genome remodeling in neuroblastoma
Richard Koche,Elias Rodriguez-Fos,Konstantin Helmsauer,Martin Burkert,Martin Burkert,Ian C. MacArthur,Jesper L.V. Maag,Rocio Chamorro,Natalia Munoz-Perez,Montserrat Puiggròs,Heathcliff Dorado Garcia,Yi Bei,Claudia Röefzaad,Victor Bardinet,Annabell Szymansky,Annika Winkler,Theresa M Thole,Natalie Timme,Katharina Kasack,Steffen Fuchs,Steffen Fuchs,Filippos Klironomos,Nina Thiessen,Eric Blanc,Karin Schmelz,Annette Künkele,Annette Künkele,Patrick Hundsdörfer,Patrick Hundsdörfer,Carolina Rosswog,Jessica Theissen,Dieter Beule,Hedwig E. Deubzer,Hedwig E. Deubzer,Hedwig E. Deubzer,Sascha Sauer,Joern Toedling,Matthias Fischer,Matthias Fischer,F Hertwig,F Hertwig,Roland F. Schwarz,Roland F. Schwarz,Angelika Eggert,Angelika Eggert,David Torrents,David Torrents,Johannes H. Schulte,Johannes H. Schulte,Anton G. Henssen +49 more
TL;DR: It is found that extrachromosomal circular DNAs are an unanticipated major source of somatic rearrangements, contributing to oncogenic remodeling through chimeric circularization and reintegration of circular DNA into the linear genome.
Journal ArticleDOI
Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition
Anton G. Henssen,Anton G. Henssen,Kristina Althoff,Andrea Odersky,Anneleen Beckers,Richard Koche,Frank Speleman,Simon Schäfers,Emma Bell,Maike Nortmeyer,Frank Westermann,Katleen De Preter,Alexandra Florin,Lukas C. Heukamp,Annika Spruessel,Kathy Astrahanseff,Sven Lindner,Natalie Sadowski,Alexander Schramm,Lucile Astorgues-Xerri,Maria E. Riveiro,Angelika Eggert,Esteban Cvitkovic,Johannes H. Schulte +23 more
TL;DR: It is shown that OTX015 is effective against mouse and human MYCN-driven tumor models and that BRD4 not only targets MYCN, but specifically occupies MYCN target gene enhancers as well as other genes associated with super-enhancers.
Journal ArticleDOI
BET bromodomain protein inhibition is a therapeutic option for medulloblastoma
Anton G. Henssen,Theresa Thor,Andrea Odersky,Lukas C. Heukamp,Nicolai El-Hindy,Anneleen Beckers,Frank Speleman,Kristina Althoff,Simon Schäfers,Alexander Schramm,Ulrich Sure,Gudrun Fleischhack,Angelika Eggert,Johannes H. Schulte +13 more
TL;DR: Preclinical data provide evidence to pursue testing BET inhibitors, such as JQ1, as molecular targeted therapeutic options for patients with high-risk medulloblastomas overexpressing MYC or harboring a MYC oncogene amplification.